for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ImmunoGen, Inc.

IMGN.OQ

Latest Trade

3.72USD

Change

-0.11(-2.87%)

Volume

155,618

Today's Range

3.66

 - 

3.84

52 Week Range

1.95

 - 

7.07

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.83
Open
3.82
Volume
155,618
3M AVG Volume
48.27
Today's High
3.84
Today's Low
3.66
52 Week High
7.07
52 Week Low
1.95
Shares Out (MIL)
174.54
Market Cap (MIL)
671.99
Forward P/E
-5.53
Dividend (Yield %)
--

Next Event

Q3 2020 ImmunoGen Inc Earnings Release

Latest Developments

More

Immunogen Reports Q2 Loss Per Share $0.14

ImmunoGen Appoints Susan Altschuller As CFO

Immunogen Announces Initial Data From Forward II Study Evaluating Mirvetuximab Soravtansine In Combination With Avastin In Recurrent Ovarian Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ImmunoGen, Inc.

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Industry

Biotechnology & Drugs

Contact Info

84 State St

BOSTON, MA

02109-2202

United States

+1.781.8950600

http://www.immunogen.com

Executive Leadership

Stephen C. McCluski

Independent Chairman of the Board

Mark J. Enyedy

President, Chief Executive Officer, Director

Susan Altschuller

Chief Financial Officer, Senior Vice President

Anna Berkenblit

Senior Vice President and Chief Medical Officer

Stacy Coen

Senior Vice President and Chief Business Officer

Key Stats

2.22 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-0.980

2018

-1.200

2019

-0.700

2020(E)

-0.686
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.77
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-35.89
Return on Equity (TTM)
-25.23

Latest News

Latest News

BRIEF-ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

* IMMUNOGEN ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

BRIEF-Immunogen Presents Initial Data From Forward II Study Evaluating Mirvetuximab Soravtansine In Combination With Avastin® In Recurrent Ovarian Cancer

* IMMUNOGEN PRESENTS INITIAL DATA AT ASCO FROM FORWARD II STUDY EVALUATING MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH AVASTIN® IN RECURRENT OVARIAN CANCER, REGARDLESS OF PLATINUM STATUS Source text for Eikon: Further company coverage:

BRIEF-Immunogen Announces Initial Data From Forward II Study Evaluating Mirvetuximab Soravtansine In Combination With Avastin In Recurrent Ovarian Cancer

* IMMUNOGEN ANNOUNCES INITIAL DATA FROM FORWARD II STUDY EVALUATING MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH AVASTIN® IN RECURRENT OVARIAN CANCER, REGARDLESS OF PLATINUM STATUS

BRIEF-Immunogen Reports Recent Progress And First Quarter 2020 Financial Results

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Immunogen Reports Q4 Earnings Per Share $0.03

* IMMUNOGEN REPORTS RECENT PROGRESS AND 2019 FINANCIAL RESULTS

ImmunoGen drug fails cancer study, shares slide 40 percent

U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving its shares more than 40 percent lower on Friday.

ImmunoGen's ovarian cancer drug fails in late-stage study

U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study.

BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination Regimens

* IMMUNOGEN ANNOUNCES POSITIVE FINDINGS FROM THE FORWARD II STUDY OF MIRVETUXIMAB SORAVTANSINE COMBINATION REGIMENS WITH AVASTIN® AND CARBOPLATIN IN OVARIAN CANCER

BRIEF-ImmunoGen Reports Q1 Loss Per Share $0.30

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2018 OPERATING RESULTS

BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine

* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER

BRIEF-Immunogen Inc Files For Potential Mixed Shelf Offering

* IMMUNOGEN INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2DablVK) Further company coverage:

BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11

* IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS

BRIEF-Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln

* IMMUNOGEN SAYS ON JAN 8, CO DISCLOSED IT EXPECTS TO REPORT THAT AS OF DEC 31, 2017 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $267.1 MILLION - SEC FILING Source text (http://bit.ly/2CRXR5Q) Further company coverage:

BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:

BRIEF-ImmunoGen reports Q3 loss per share $0.61

* ImmunoGen reports recent progress and third quarter 2017 operating results

BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

* Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

BRIEF-Immunogen prices offering of 14.5 mln common shares at $6.50 per share

* Immunogen announces pricing of public offering of common stock

BRIEF-Immunogen- As of Sept. 30, had cash and cash equivalents of about $194.9 mln

* Immunogen- on Oct, 4,, co disclosed that it expects to report that as of Sept. 30, 2017 it had cash and cash equivalents of about $194.9 million Source: (http://bit.ly/2gcIozK) Further company coverage:

BRIEF-ImmunoGen intends to offer and sell 13 mln shares of common stock​

* ImmunoGen announces proposed public offering of common stock

BRIEF-Immunogen enters privately negotiated exchange agreements

* Immunogen-on Sept 25, co entered privately negotiated exchange agreements with some holders of co's outstanding 4.50% convertible senior notes due 2021

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up